The American Journal of Medicine
Volume 121, Issue 8 , Pages 647-655 , August 2008

Psychotropic Drug Considerations in Depressed Patients with Metabolic Disturbances

  • W. Victor R. Vieweg, MD

      Affiliations

    • Psychiatry Service, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Va
    • Medicine Service, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Va
    • Department of Psychiatry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond
    • Department of Internal Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond
    • Corresponding Author InformationReprint requests should be addressed to Victor Vieweg, MD, 17 Runswick Drive, Richmond, VA 23238-5414.
    • ,
  • James R. Levy, MD

      Affiliations

    • Medicine Service, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Va
    • Department of Internal Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond
    • ,
  • Sonja K. Fredrickson, MD

      Affiliations

    • Medicine Service, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Va
    • Department of Internal Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond
    • ,
  • Stuart R. Chipkin, MD

      Affiliations

    • School of Public Health and Health Sciences, University of Massachusetts, Amherst
    • ,
  • Mary Beatty-Brooks, MA

      Affiliations

    • Medical Media, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Va
    • ,
  • Antony Fernandez, MD

      Affiliations

    • Psychiatry Service, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Va
    • Department of Psychiatry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond
    • ,
  • Mehrul Hasnain, MD

      Affiliations

    • Department of Psychiatry, Western Regional Integrated Health Authority, Sir Thomas Roddick Hospital, Stephenville, Newfoundland, Canada.
    • ,
  • Anand K. Pandurangi, MD

      Affiliations

    • Department of Psychiatry, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond

References 

  1. Kessler RC, Berglund P, Demler O, et al. The Epidemiology of Major Depressive Disorder: Results From the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095–3105
  2. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55:694–700
  3. Keller MB, Lavori PW, Rice J, et al. The persistent risk of chronicity in recurrent episodes of nonbipolar major depressive disorder: a prospective follow-up. Am J Psychiatry. 1986;143:24–28
  4. Ustin TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry. 2004;184:386–392
  5. Bloom BS. Prevalence and economic effects of depression. Manag Care. 2004;13(6 suppl depression):9–16
  6. Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord. 2002;68:167–181
  7. Stark C, Hall D, O'Brien F, Smith H. Suicide after discharge from psychiatric hospitals in Scotland. BMJ. 1995;311:1368–1369
  8. Mitchell AJ. Depressed patients and treatment adherence. Lancet. 2006;367:2041–2043
  9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults (Findings from the Third National Health and Nutrition Examination Survey). JAMA. 2002;287:356–359
  10. Benazzi F. Weight gain in depression remitted with antidepressants: pharmacological or recovery effect?. Psychother Psychosom. 1998;67:271–274
  11. Fava M. Weight gain and antidepressants. J Clin Psychiatry. 2000;61(suppl 11):37–41
  12. Vieweg WVR, Adler RA, Fernandez A. Weight control and antipsychotics (How to tip the scales away from diabetes and heart disease). Current Psychiatry. 2002;1:10–19
  13. Vieweg WVR, Thomas M, Janisko M, et al. Patient and direct-care staff body mass index in a state mental hospital (Implications for management). Acta Psychiatr Scand. 2004;110:69–72
  14. Vieweg WVR, Sood AB, Pandurangi A, Silverman JJ. Choose precise BMI charts to track youths' weight gain. Current Psychiatry. 2004;3:86
  15. Vieweg WVR, Sood AB, Pandurangi A, Silverman JJ. Newer antipsychotic drugs and obesity in children and adolescents (How should we assess drug-associated weight gain?). Acta Psychiatr Scand. 2005;111:177–184
  16. Vieweg WVR, Kuhnley LJ, Kuhnley EJ, et al. Body mass index (BMI) in newly admitted child and adolescent psychiatric inpatients. Prog Neuropsychopharm Biol Psychiatry. 2005;29:511–515
  17. Vieweg WVR, Maxfield M, Lewis RE, et al. Direct-care staff body mass index in a state mental hospital (Potential implications for Black Americans). Neuro-Psychopharmacol Biol Psychiatry. 2005;29:989–991
  18. Vieweg WVR, Julius DA, Fernandez A, et al. Posttraumatic stress disorder in male military veterans with comorbid overweight and obesity (Psychotropic, antihypertensive, and metabolic medications). Primary Care Companion J Clin Psychiatry. 2006;8:25–31
  19. Ackerman S, Nolan LJ. Bodyweight gain induced by psychotropic drugs (Incidence, mechanisms, and management). CNS Drugs. 1998;9:135–151
  20. Goodnick PJ. Seligiline transdermal system in depression. Expert Opin Pharmacother. 2007;8:59–64
  21. Erich JL, Shih RD, O'Connor RE. “Ping-pong” gaze in severe monoamine oxidase inhibitor toxicity. J Emerg Med. 1995;13:653–655
  22. Vieweg WVR, Wood MA. Tricyclic antidepressants, QT interval prolongation, and torsade de pointes. Psychosomatics. 2004;45:371–377
  23. Shireman TI, Rigler SK, Jachna CM, et al. The cost effect of newer medication adoption in an order Medicaid cohort. J Am Geriatr Soc. 2005;53:1366–1373
  24. American Diabetes Association. American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity (Consensus development conference on antipsychotic drugs and obesity and diabetes). Diabetes Care. 2004;27:596–601
  25. Fava M, Rush AJ, Trivedi MH, et al. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am. 2003;26:457–494
  26. Rush AJ, Fava M, Wisniewski SR, et al. Sequenced Treatment Alternatives to Relieve Depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119–142
  27. Rush AJ. STAR*D: what have we learned?. Am J Psychiatry. 2007;164:201–204
  28. Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry. 2007;164:739–752
  29. Wisniewski SR, Fava M, Trivedi MH, et al. Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry. 2007;164:753–760
  30. Rush AJ, Trivedi M, Fava M. STAR*D treatment trial for depression. Am J Psychiatry. 2007;160:237
  31. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51:480–491
  32. Ginsberg HN. Treatment for patients with the metabolic syndrome. Am J Cardiol. 2003;91(suppl):29E–39E
  33. Vieweg WVR, Julius DA, Fernandez A, et al. Treatment of depression in patients with coronary heart disease. Am J Med. 2006;119:567–573
  34. Bright RA, Everitt DE. Beta-blockers and depression (Evidence against an association). JAMA. 1992;267:1783–1787
  35. Fernandez A, Bang SE, Srivathsan K, Vieweg WVR. Cardiovascular side effects of newer antidepressants (A review). Anadolu Kardiyol Derg. 2007;7:305–309
  36. Himmerich H, Schuld A, Haack M, et al. Early prediction of changes in weight gain during six weeks of treatment with antidepressants. J Psychiatr Res. 2004;38:485–489
  37. Schwartz TL, Meszaros ZS, Khan R, Nihalani N. How to control weight gain when prescribing antidepressants. Current Psychiatry. 2007;6:43–54
  38. DeMaria EJ. Bariatric surgery for morbid obesity. N Engl J Med. 2007;356:2176–2183
  39. Reaven GM. The metabolic syndrome: is this diagnosis necessary?. Am J Clin Nutr. 2006;83:1237–1247
  40. Alberti KG, Zimmet PZ. Definition, diagnosis, and classification of diabetes mellitus and its complications (Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation). Diabet Med. 1998;15:539–553
  41. Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)). JAMA. 2001;285:2486–2497
  42. International Diabetes Foundation. The IDF consensus worldwide definition of the metabolic syndrome. Part 1. Worldwide definition for use in clinical practice. Accessed July 25 http://www idf org/webdata/docs/MetS_def_update2006 pdfAccessed July 25, 2007.
  43. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686–1696
  44. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry. 2001;62(suppl 7):22–31
  45. Aronne LJ, Segal KR. Weight gain in the treatment of mood disorders. J Clin Psychiatry. 2003;64(suppl 8):22–29
  46. Biton V, Mirza W, Montouris G, et al. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001;56:172–177
  47. Brecher M, Rak IW, Westhead EK. The long-term effect of quetiapine (‘Seroquel') monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract. 2000;4:287–292
  48. Breier A, Tanaka Y, Roychowdhury S, Clark WS. Nizatidine for the prevention of olanzapine-associated weight gain in schizophrenia and related disorders. A randomized controlled double blind study. 41st annual meeting of the New Clinical Drug Evaluation Unit, Phoenix, Arizona, May 28-31, 2001.
  49. Bustillo JR, Lauriello J, Parker K, et al. Treatment of weight gain with fluoxetine in olanzapine-treated schizophrenic outpatients. Neuropsychopharmacology. 2003;28:527–529
  50. Casey DE, Zorn SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry. 2001;62(suppl 7):4–10
  51. Delvin MJ, Yanovski SZ, Wilson GT. Obesity: what mental health professionals need to know. Am J Psychiatry. 2000;157:854–866
  52. Dickerson FB, Brown CH, Kreyenbuhl JA, et al. Obesity among individuals with serious mental illness. Acta Psychiatr Scand. 2006;113:306–313
  53. Dursun SM, Devarajan S. Clozapine weight gain, plus topiramate weight loss. Can J Psychiatry. 2000;45:198
  54. Eder U, Mangweth B, Ebenbichler C, et al. Association of olanzapine-induced weight gain with an increase in body fat. Am J Psychiatry. 2001;158:1719–1722
  55. Erfurth A, Kuhn G. Topiramate monotherapy in the maintenance treatment of bipolar I disorder: effects on mood, weight and serum lipids. Neuropsychobiology. 2000;42(suppl 1):50–51
  56. Floris M, Lejeune J, Deberdt W. Effect of amantadine on weight gain during olanzapine treatment. Eur Neuropsychopharmacology. 2001;11:181–182
  57. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res. 2001;101:277–288
  58. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clinj Psychopharmacol. 2000;20:607–614
  59. Gidal BE, Maly MM, Nemire RE, Haley K. Weight gain and gabapentin therapy. Ann Pharmacother. 1995;29:1048
  60. Greenberg I, Chan S, Blackburn GL. Nonpharmacologic and pharmacologic management of weight gain. J Clin Psychiatry. 1999;60(suppl 21):31–36
  61. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med. 2005;143:415–426
  62. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000;157:975–981
  63. Horrigan JP, Barnhill LJ, Kohli RR. Adderall, the atypicals, and weight gain. J Am Acad Child Adolesc Psychiatry. 2001;40:620
  64. Kabinoff GS, Toalson PA, Healey KM, et al. Metabolic issues with atypical antipsychotics in primary care: dispelling the myths. Prim Care Companion J Clin Psychiatry. 2003;5:6–14
  65. Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol. 1998;8:151–159
  66. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62:92–100
  67. Koga M, Nakayama K. Body weight gain induced by a newer antipsychotic agent reversed as negative symptoms improved. Acta Psychiatr Scand. 2005;112:75–76
  68. Koller E, Schneider B, Bennett K, Dubitsky G. Clozapine-associated diabetes. Am J Med. 2001;111:716–723
  69. Koller EA, Doraiswamy M. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841–852
  70. Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry. 2002;63:1045
  71. Littrell KH, Petty RG, Hilligoss NM, et al. Educational interventions for the management of antipsychotic-related weight gain. 41st annual meeting of the New Clinical Drug Evaluation Unit, Phoenix, Arizona, May 28-31, 2001.
  72. Malhi GS, Mitchell PB, Caterson I. ‘Why getting fat, Doc?' (Weight gain and psychotropic medications). Aust N Z J Psychiatry. 2001;35:315–321
  73. Malhotra S, McElroy SL. Medical management of obesity associated with mental disorders. J Clin Psychiatry. 2002;63(suppl 4):24–32
  74. McElroy SL, Kotwal R, Malhotra S, et al. Are mood disorders and obesity related? (A review for the mental health professional). J Clin Psychiatry. 2004;65:634–651
  75. Meyer JM. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry. 2002;63:425–433
  76. Morrison JA, Cottingham EM, Barton BA. Metformin for weight loss in pediatric patients taking psychotropic drugs. Am J Psychiatry. 2002;159:655–657
  77. Moyers SB. Medications as adjunct therapy for weight loss: approved and off-label agents in use. J Am Diet Assoc. 2005;105:948–959
  78. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37:68–73
  79. Mustillo S, Worthman C, Erkanli A, et al. Obesity and psychiatric disorder: developmental trajectories. Pediatrics. 2003;111:851–859
  80. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002;59:337–345
  81. Planasky K. Changes in weight in patients receiving a tranquilizing drug. Psychiatr Q. 1958;32:289–303
  82. Poyurovsky M, Pashinian A, Gil-Ad I, et al. Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. Am J Psychiatry. 2002;159:1058–1060
  83. Reinstein MJ, Sirotovskaya LA, Jones LE, et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest. 1999;18:99–104
  84. Reynolds GP, Zhang Z, Zhang X. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359:2086–2087
  85. Rotatori AF, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self-control program. Psychol Rep. 1980;6:483–486
  86. Sacchetti E, Guarneri L, Bravi D. H2 antagonist nizatidine may control olanzapine-associated weight gain in schizophrenic patients. Biol Psychiatry. 2000;48:167–168
  87. Sargent PA, Sharpley AL, Williams C, et al. 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacol. 1997;133:309–312
  88. Simon GE, Von Korff M, Saunders K, et al. Association between obesity and psychiatric disorders in the US adult population. Arch Gen Psychiatry. 2006;63:824–830
  89. Sletten I, Mou B, Cazenave M, Gershon S. Effects of caloric restriction on behavior and body weight during chlorpromazine therapy. Dis Nerv Syst. 1967;28:519–522
  90. Stahl SM. Neuropharmacology of obesity: my receptors made me eat it. J Clin Psychiatry. 1998;59:447–448
  91. Stahl SM. How to appease the appetite of psychotropic drugs. J Clin Psychiatry. 1998;59:500–501
  92. Sussman N. Review of atypical antipsychotics and weight gain. J Clin Psychiatry. 2001;62(suppl 23):5–12
  93. Theisen FM, Linden A, Geller F, et al. Prevalence of obesity in adolescent and young adults with and without schizophrenia and in relationship to antipsychotic medication. J Psychiatr Res. 2001;35:339–345
  94. Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatric Services. 2002;53:842–847
  95. Werneke U, Taylor D, Sanders TAB. Options for pharmacological management of obesity in patients treated with atypical antipsychotics. Int Clin Psychopharmacol. 2002;17:145–160
  96. Wirshing DA, Spellberg B, Erhart S, et al. Novel antipsychotics and new onset diabetes. Biol Psychiatry. 1998;44:778–783
  97. Wirshing DA, Wirshing WC, Kysar L, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry. 1999;60:358–363

PII: S0002-9343(08)00039-9

doi: 10.1016/j.amjmed.2007.08.043

The American Journal of Medicine
Volume 121, Issue 8 , Pages 647-655 , August 2008

Article Tools

* Image Usage & Resolution